Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in New York
10 open options
- TRIALNARECRUITING
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
Symani Surgical System — 3 sites
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 212 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALNANOT_YET_RECRUITING
Sleep Interventions and Neurocognitive Outcomes
Acoustic slow-wave activity enhancement · Cognitive behavioral therapy for insomnia — 1 site
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALNARECRUITING
Olfactory Training in Mild Cognitive Impairment
Olfactory Memory Training · Visual Memory Training — 1 site
- TRIALNARECRUITING
The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study
Positive airway pressure · Oral appliance therapy · Positional therapy — 4 sites
- TRIALPHASE3RECRUITING
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Trontinemab · Placebo — 143 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
KarXT · KarX-EC · Placebo — 126 sites
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.